The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo
- 19 August 2010
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 335 (2), 362-368
- https://doi.org/10.1124/jpet.110.166181
Abstract
Palonosetron is the only 5-HT(3) receptor antagonist approved for the treatment of delayed chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic chemotherapy. Accumulating evidence suggests that substance P (SP), the endogenous ligand acting preferentially on neurokinin-1 (NK-1) receptors, not serotonin (5-HT), is the dominant mediator of delayed emesis. However, palonosetron does not bind to the NK-1 receptor. Recent data have revealed cross-talk between the NK-1 and 5HT(3) receptor signaling pathways; we postulated that if palonosetron differentially inhibited NK-1/5-HT(3) cross-talk, it could help explain its efficacy profile in delayed emesis. Consequently, we evaluated the effect of palonosetron, granisetron, and ondansetron on SP-induced responses in vitro and in vivo. NG108-15 cells were preincubated with palonosetron, granisetron, or ondansetron; antagonists were removed and the effect on serotonin enhancement of SP-induced calcium release was measured. In the absence of antagonist, serotonin enhanced SP-induced calcium-ion release. After preincubation with palonosetron, but not ondansetron or granisetron, the serotonin enhancement of the SP response was inhibited. Rats were treated with cisplatin and either palonosetron, granisetron, or ondansetron. At various times after dosing, single neuronal recordings from nodose ganglia were collected after stimulation with SP; nodose ganglia neuronal responses to SP were enhanced when the animals were pretreated with cisplatin. Palonosetron, but not ondansetron or granisetron, dose-dependently inhibited the cisplatin-induced SP enhancement. The results are consistent with previous data showing that palonosetron exhibits distinct pharmacology versus the older 5-HT(3) receptor antagonists and provide a rationale for the efficacy observed with palonosetron in delayed CINV in the clinic.Keywords
This publication has 21 references indexed in Scilit:
- 608 Upregulation of Vagal NK1 Receptor By Cisplatin Facilitates the Interaction of Substance P and Serotonin in the Vagal Afferent Neurons: Implication in the Emesis Related to ChemotherapyGastroenterology, 2009
- Dose‐independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first‐pass effects to low bioavailabilityBiopharmaceutics & Drug Disposition, 2008
- Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 ReceptorAnesthesia & Analgesia, 2008
- Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 2008
- A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyAnnals of Oncology, 2006
- Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neuronsNeuroscience Letters, 2004
- Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonistCancer, 2003
- Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsEuropean Journal Of Cancer, 2003
- Characteristics of [14C]Guanidinium Accumulation in NG 108‐15 Cell Exposed to Serotonin 5‐HT3 Receptor Ligands and Substance PJournal of Neurochemistry, 1993
- Substance P and serotonin act synergistically to activate a cation permeability in a neuronal cell lineBrain Research, 1989